Long-term safety of Etrasimod in ulcerative colitis: a comprehensive review

Etrasimod is an oral sphingosine-1-phosphate receptor modulator approved for the treatment of moderate to severe ulcerative colitis. Its targeted mechanism, once-daily dosing and oral formulation make it an important addition to the therapeutic landscape. However, its safety profile and optimal clinical positioning require careful evaluation.

This narrative review examines the pharmacology, efficacy and safety of etrasimod in ulcerative colitis, drawing on evidence from the OASIS, ELEVATE UC and ENLIGHT UC trial programmes, open-label extension studies, meta-analyses, pharmacovigilance reports and emerging real-world cohorts. The practicalities of prescribing and monitoring are also covered. A literature search was conducted in MEDLINE to identify appropriate studies.

Current evidence supports etrasimod as a generally well-tolerated treatment option, with low rates of serious adverse events, serious infections, opportunistic infections and malignancy which do not differ substantially from placebo. Key safety considerations include first-dose bradycardia, atrioventricular conduction abnormalities, macular oedema, hepatic enzyme elevations, and lymphopenia, all of which necessitate appropriate screening and monitoring. Etrasimod may be particularly useful in patients with moderately active disease and limited prior advanced therapy exposure, whilst its reassuring safety profile and low risk of serious infection make it an attractive candidate for use in advanced combination therapy.